Current approaches toward PROTAC-mediated degradation within AD are focused on the targeted degradation of tau and hydrophobic tagging of tau that does not rely on E3 ligase recruitment (Gao et al., 2017b; Hyun and Shin, 2021). Here, MAPT is linked to Alzheimer disease.